Perlara embarks on journeys of discovery called PerlQuests™ with families and patient organizations to develop treatments for rare diseases.
There are about 7000 rare diseases affecting 350 million people worldwide, of which roughly half are inherited, i.e. relating to genes. Until now, the cost of discovering chemical compounds that might be safe and effective candidates for the development of an FDA approved drug therapy has been too high for “rare” diseases affecting small populations. At the current rate of new drug approvals, it will take another 450 years before drugs are approved for all rare diseases.
Our PerlArk™ Drug Discovery Platform increases the speed and lowers the cost of cure discovery by rapidly screening thousands of potential drug candidates, providing new hope for millions of rare disease patients.
We have identified at least 250 single-gene diseases that fit our PerlArk™ Platform. These diseases share some overlap with common diseases, allowing us to begin the quest for treatments for over 1000 diseases. Our first PerlQuests target Niemann-Pick C Disease (NPC) and Niemann-Pick A Disease (NPA), lysosomal storage disorders, NGLY1 Deficiency, a metabolic disease related to proteasome-mediated degradation, and PMM2-CDG, a congenital disorder of glycosylation. What we are learning from the NPC PerlQuest may lead to drug candidates for Alzheimer’s disease.
Let’s PerlQuest together
Still have questions about PerlQuests?
Follow a PerlQuest
Research updates from our Blog
I just attended the 2018 Michael, Marcia, and Christa Parseghian Scientific Conference for Niemann-Pick Type C (NPC) research. My mind is still spinning from all the productive interactions and conversations I had over three session-packed days at The Westin La...
An update on the development of PMM2 Drosophila models, and our work to design high throughput drug screen for PMM2 deficiency — Phosphomannomutase 2 deficiency (PMM2-CDG) is the most common type of congenital disorder of glycosylation resulting from a defect in...
Drug repurposing screen in haploid PMM2-CDG yeast models During Stage 1 of our PerlQuest partnership with Maggie’s Cure, we generated haploid PMM2-CDG yeast models of three pathogenic variants: F119L, R141H, and V231M. We expressed these variants in the yeast...